Gene · 10189
Papers1,565
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 1,565
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| m5C-modified circRREB1 promotes lung cancer progression by inducing mitophagy. | J Exp Clin Cancer Res | 2025 | 40653497 | PubTator, text mining | PubMed |
| MAGI2-AS3/miR-450b-5p/COLEC10 interaction network: A potential therapeutic and prognostic marker in hepatocellular carcinoma. | ILIVER | 2025 | 40636781 | PubTator, text mining | PubMed |
| Structural basis for the synergistic assembly of the snRNA export complex. | Nat Struct Mol Biol | 2025 | 40610714 | PubTator, text mining | PubMed |
| BAP31 Promotes Epithelial-Mesenchymal Transition Progression Through the Exosomal miR-423-3p/Bim Axis in Colorectal Cancer. | Int J Mol Sci | 2025 | 40564945 | PubTator, text mining | PubMed |
| The m5C reader Alyref regulates cardiac remodeling post-myocardial infarction by modulating extracellular matrix protein synthesis in cardiac fibroblasts. | Biochim Biophys Acta Mol Cell Res | 2025 | 40562236 | PubTator, text mining | PubMed |
| RNA Through Time: From the Origin of Life to Therapeutic Frontiers in Transcriptomics and Epitranscriptional Medicine. | Int J Mol Sci | 2025 | 40507776 | PubTator, text mining | PubMed |
| ALYREF regulates the m5C modification and stability of BIRC5 mRNA to promote ovarian cancer progression. | Pathol Res Pract | 2025 | 40479805 | PubTator, text mining | PubMed |
| CircHIPK3's dual role in promoting angiogenesis and inhibiting apoptosis through FASN mRNA stabilization in gallbladder cancer. | Clinics (Sao Paulo) | 2025 | 40466438 | PubTator, text mining | PubMed |
| Translational Regulation of Plant Stress Responses: Mechanisms, Pathways, and Applications in Bioengineering. | Annu Rev Phytopathol | 2025 | 40455831 | PubTator, text mining | PubMed |
| RNA m5C modification: from physiology to pathology and its biological significance. | Front Immunol | 2025 | 40370440 | PubTator, text mining | PubMed |
| ALYREF Promotes Progression of Intrahepatic Cholangiocarcinoma through Increasing the Level of Isocitrate Dehydrogenase 1 in an m5C-Dependent Manner. | Mol Cell Biol | 2025 | 40369958 | PubTator, text mining | PubMed |
| ETV4/ALYREF-mediated glycolytic metabolism through PKM2 enhances resistance to ferroptosis and promotes the development of intrahepatic cholangiocarcinoma. | Cancer Metab | 2025 | 40264211 | PubTator, text mining | PubMed |
| Exploring the impact of cuproptosis on prostate cancer prognosis via RNA methylation regulation based on single cell and bulk RNA sequencing data. | Front Pharmacol | 2025 | 40235543 | PubTator, text mining | PubMed |
| YTHDC1 phase separation drives the nuclear export of m6A-modified lncNONMMUT062668.2 through the transport complex SRSF3-ALYREF-XPO5 to aggravate pulmonary fibrosis. | Cell Death Dis | 2025 | 40221424 | PubTator, text mining | PubMed |
| Aberrant CircTMEM45A Facilitates Inflammatory Progression of Esophageal Squamous Cell Carcinoma through m5C-Mediated NLRP3 Activation. | Cancer Res | 2025 | 40215175 | PubTator, text mining | PubMed |
| The mRNA export pathway licenses viral mimicry response and antitumor immunity by actively exporting nuclear retroelement transcripts. | Sci Transl Med | 2025 | 40203080 | PubTator, text mining | PubMed |
| Transcriptome-wide identification of 5-methylcytosine by deaminase and reader protein-assisted sequencing. | Elife | 2025 | 40197347 | PubTator, text mining | PubMed |
| NSUN2/ALYREF-medicated m5C-modified circRNA505 regulates the proliferation, differentiation, and glycolysis of antler chondrocytes via the miRNA-127/p53 axis and LDHA. | Int J Biol Macromol | 2025 | 40147663 | PubTator, text mining | PubMed |
| Epigenetic ALYREF/UHRF1/RHOB Axis in Corneal Wound Healing and Implications for Epithelial Tumorigenesis. | Invest Ophthalmol Vis Sci | 2025 | 40131294 | PubTator, text mining | PubMed |
| NSUN2/ALYREF axis-driven m5C methylation enhances PD-L1 expression and facilitates immune evasion in non-small-cell lung cancer. | Cancer Immunol Immunother | 2025 | 40029463 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10189/papers?page=5